South Korean contract development and manufacturing organisation (CDMO) Samsung Biologics has been awarded the Sustainability Leadership Award at the 2026 CDMO Leadership Awards, presented by Outsourced Pharma and Life Science Connect.
The award recognises efforts to advance sustainable practices across its operations and value chain.
Samsung Biologics was also named "Best in Class" in Cultural Fit in the 'Biologics—Large CDMOs' category, reflecting its strong, collaborative partnerships built on "shared goals" and "close alignment with client needs."
The CDMO Leadership Awards recognise top-performing CDMOs based on global client feedback regarding facilities, innovation, technical expertise and manufacturing capabilities.
The Jury Awards, determined by an independent panel of industry experts using survey data, highlight the best in the field.
At the recent DCAT Week awards ceremony in New York, Samsung Biologics stated that this recognition reflects its commitment to stable, sustainable practices that support client programmes.
"Sustainability is a core value at Samsung Biologics and guides how we pursue excellence throughout our business and partnerships," said John Rim, President and CEO of Samsung Biologics, who also serves as champion for the Sustainable Markets Initiative (SMI) Supply Chains Working Group.
This recognition reflects the trust our clients and partners continue to place in us, as well as the dedication of our teams who consistently strive to integrate sustainable practices across our operations.
"We will continue to advance these efforts in close collaboration with our partners, supporting their long-term goals and the delivery of high-quality, life-saving medicines to patients worldwide."
Samsung Biologics recently achieved a Platinum rating from EcoVadis, which recognises top-performing companies worldwide for their sustainability practices.
The company has also implemented a product carbon footprint (PCF) system that has been independently validated, ensuring transparent and consistent measurement of emissions.
Additionally, while continuing its role as a Champion of the SMI Health Systems Task Force, Samsung Biologics plans to enhance engagement with global suppliers to accelerate decarbonisation efforts and develop more resilient value chains.